Streetbeat News

RNAZ

TransCode Therapeutics, Inc.

https://www.transcodetherapeutics.com

Industry

Biotechnology

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Open

0.48

Mkt cap

7.8M

Volume

219K

High

0.48

P/E Ratio

N/A

52-wk high

18.68

Low

0.45

Div yield

N/A

52-wk low

0.22

TransCode Therapeutics announced a public offering of common stock, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:19 pm

The Nasdaq Composite gained over 100 points, driven by strong earnings from Amazon. Amazon's Q3 revenue increased 13% YoY to $143.1 billion, beating estimates, and expects Q4 revenue between $160 billion and $167 billion. Other stocks that saw significant movement include Apollomics, BIO-key International, and SeaStar Medical Holding which saw increases, while Siyata Mobile, Medicenna Therapeutics, and TransCode Therapeutics saw decreases.

Portfolio Pulse from Lisa Levin

October 27, 2023 | 1:44 pm

In Friday's pre-market session, several healthcare stocks experienced significant movement. Apollomics (APLM), SeaStar Medical Holding (ICU), CVRx (CVRX), ABVC BioPharma (ABVC), DexCom (DXCM), and Jin Medical International (ZJYL) saw gains, while TransCode Therapeutics (RNAZ), PTC Therapeutics (PTCT), Pasithea Therapeutics (KTTA), Sanofi (SNY), PaxMedica (PXMD), and Nexalin Technology (NXL) experienced losses. Q3 earnings reports were recently released for CVRx, DexCom, PTC Therapeutics, and Sanofi.

Portfolio Pulse from Benzinga Insights

October 27, 2023 | 1:05 pm

Intel Corporation and Amazon.com, Inc. shares are trading higher in pre-market due to better-than-expected Q3 results and strong guidance for the current quarter. Other companies such as NKGen Biotech, SeaStar Medical Holding, and Apollomics also saw a rise in their shares. However, companies like TransCode Therapeutics, Enphase Energy, and Sanofi saw a dip in their shares due to various reasons such as public offering of common stock, lower Q3 revenue, and weak guidance for Q4.

Portfolio Pulse from Lisa Levin

October 27, 2023 | 12:14 pm

TransCode Therapeutics has been granted an extension for continued listing on the Nasdaq Stock Market, subject to certain conditions. The extension was granted by a Nasdaq Panel.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 12:07 pm

Healthcare stocks showed significant movement in Thursday's after-market session. CVRx, SeaStar Medical Holding, Eargo, DexCom, China SXT Pharmaceuticals, and Alaunos Therapeutics saw gains, while TransCode Therapeutics, PTC Therapeutics, ContraFect, Bio-Rad Laboratories, Day One Biopharmaceutical, and Processa Pharma experienced losses. Q3 earnings reports were released for CVRx, DexCom, PTC Therapeutics, and Bio-Rad Laboratories.

Portfolio Pulse from Benzinga Insights

October 26, 2023 | 9:31 pm

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) has announced the commencement of an underwritten public offering of its common stock. The company also expects to grant the underwriters a 45-day option to purchase additional shares equal to 15% of the shares offered in the public offering. The offering is subject to market and other conditions, and there is no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. ThinkEquity is acting as sole book-running manager for the offering.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 8:36 pm

The article lists the stocks that gained and lost the most during Thursday's mid-day trading session. Among the gainers were ABVC BioPharma, PaxMedica, and NextPlay Technologies, which saw significant increases due to various positive developments such as licensing deals, FDA meetings, and better-than-expected revenue results. On the other hand, stocks like Bit Brother, Sight Sciences, and Sonoma Pharmaceuticals experienced significant drops due to factors like pricing of direct offerings and weak sales forecasts.

Portfolio Pulse from Lisa Levin

October 26, 2023 | 5:27 pm

In Thursday's pre-market session, several healthcare stocks saw significant movement. ABVC BioPharma, PaxMedica, TransCode Therapeutics, Oncternal Therapeutics, Evaxion Biotech, and Blue Water Biotech were among the gainers, with ABVC BioPharma leading with a 348.2% increase. On the other hand, Sonoma Pharmaceuticals, Align Tech, Cognition Therapeutics, LumiraDx, Aclarion, and Nexalin Technology were among the losers, with Sonoma Pharmaceuticals leading the decline with a 26.4% decrease.

Portfolio Pulse from Benzinga Insights

October 26, 2023 | 1:06 pm

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced improved survival in murine models bearing human glioblastoma multiforme (GBM) tumors treated with its lead therapeutic candidate, TTX-MC138. The study showed that mice treated with TTX-MC138 survived significantly longer than those in the control group. TransCode believes that TTX-MC138 could be an alternative treatment in cases where resistance to standard-of-care chemotherapy has occurred. The company is enrolling patients in a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 12:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.